Synopsis:
- Novozymes and Novo Nordisk Pharmatech are joining forces to develop best-in-class technical enzymes to support production processes in the biopharmaceutical industry.
Novo Nordisk Pharmatech and Novozymes enter into Enzyme Partnership.
Novozymes and Novo Nordisk Pharmatech have announced a collaboration agreement that brings together the companies’ shared competencies and interests in the development of specialty enzymes for use in biopharma processing and regenerative medicines. Novozymes and Novo Nordisk Pharmatech announce a collaboration agreement that combines the companies’ joint competencies and interests within the development of specialty enzymes for use in biopharma processing and regenerative medicines.
Enzymes used in biopharmaceutical processing make up a small part of the 15 billion DKK market for specialty enzymes, with yearly expected growth rates in the high-single digits.
The demand for specialty enzymes is driven by the production of proteins and cells in the biopharmaceutical industry. Older production technologies are increasingly being replaced by enzymatic alternatives, particularly apparent for regenerative medicines, which additionally require high quality, pharmaceutical grade enzymes.
Together, Novozymes and Novo Nordisk Pharmatech, who both have a joint majority ownership by the Novo Nordisk Foundation, will develop such high-quality enzymatic processing aids for the regenerative medicines market, with a focus on stem cell and gene therapies.
“I am very excited about this collaboration, where synergies between the companies in the Novo Group will come into play and with the prospect of enabling scale-up of processes in the regenerative medicines market,” CEO of Novo Nordisk Pharmatech Ulla Grove Krogsgaard Thomsen says.
An initial product is expected to be brought to commercialization within a few years.
“This collaboration reinforces a shared commitment to the development of specialty enzymes. Novo Nordisk Pharmatech brings market knowledge and the required production-quality capabilities, while Novozymes brings a large enzyme library and strong R&D competencies. Together, this positions us well to create new and innovative products for this market,” says Lotte Clemmen Christensen, VP, Corporate Strategy & New Business Development at Novozymes.
The specialty enzymes market:
According to MarketsandMarkets, the specialty enzymes market is estimated to be valued at USD 4.4 billion in 2019 and is projected to reach USD 6.6 billion by 2025, recording a CAGR of 6.9% in terms of value. The rise in demand for non-harmful biological catalysts in pharmaceuticals & diagnostics led to the growth of the market. In addition, the advancement of tools to optimize pharmaceutical production and quality concerns among people have increased the usage of specialty enzymes. Factors such as the multifunctional benefits of specialty enzymes across various applications and technological innovations to reduce the consumption of chemical catalysts are contributing to the growth of the specialty enzyme market.
By type, the polymerases & nucleases segment is projected to account for the largest share in the specialty enzymes market during the forecast period:
The polymerases & nucleases segment is projected to dominate the market during the forecast period. Polymerases & nucleases are used in specialty applications, such as pharmaceuticals, research & biotechnology, diagnostics, and biocatalysts. Polymerases & nucleases have been grouped together as they both work on nucleic acid polymers such as ribonucleic acid (RNA) and deoxyribonucleic acid (DNA), and are commonly used in similar applications. These types of enzymes catalyze the synthesis of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) polymers, as they are essential for all nucleic acid processing, including replication, repair, recombination, and transcription.
By application, the pharmaceuticals segment accounted for the largest market size in the specialty enzymes market during the forecast period:
The demand for specialty enzymes is increasing significantly due to the increasing application of enzymes in the pharmaceutical industry. Specialty enzyme usage in the pharmaceutical industry is mainly for drug manufacture, disease diagnostics, or as therapy. Increasing incorporation of enzymes in therapies for diseases such as cancer, cardiovascular diseases, lysosomal storage disorders, and pain and inflammation management, among others, is a factor that fuels market demand.
North America is projected to account for the largest market share during the forecast period.
In 2018, North America accounted for the largest market share in the specialty enzymes market. Technological advancements in this region have made enzymes available for a wide range of applications, and this segment is estimated to drive the growth of the market in the region. This region is projected to be the largest market due to the development of novel and superior performing products and global industrialization. The pharmaceutical industry in this region is also witnessing a rise in the usage of enzymes. The US is the dominant country, and the market in this region has reached its maturity. These factors are projected to contribute to the growth of the North American market.
About Novo Nordisk Pharmatech:
Novo Nordisk Pharmatech is a global and leading manufacturer of pharmaceutical aids for the pharmaceutical and biopharmaceutical industries. The company specializes in producing quaternary ammonium compounds (Quats) used as active pharmaceutical ingredients (APIs) and excipients as well as Recombinant Insulin for use in cell culture media to enhance cell growth and viability, and productivity.
Novo Nordisk Pharmatech A/S helps the world´s largest pharmaceutical and biopharmaceutical industries reducing their risk for raw materials by using pharma-grade products with a high level of consistency, purity, quality, and reliability.
Novo Nordisk Pharmatech A/S was established in 1949 as Ferrosan Fine Chemicals and acquired by Novo Nordisk in 1986. The company is operating as a division of Novo Nordisk A/S from Køge, south of Copenhagen.
Recent market developments
In March 2021, Novo Nordisk Pharmatech launched a superior Good Manufacturing Practice (GMP) grade recombinant trypsin in anticipation of expansion of their portfolio by introducing more enzymes and purification resins in the future.
DuPont Nutrition & Biosciences announced its industry-leading OPTIMASE rage in April 2019, featuring bio-based enzymes that are utilized to clean medical devices.
In January 2021, SciTech Specialties Private Limited was acquired by Advanced Enzyme Technologies Limited for a 51% controlling share.
About Novozymes:
Novozymes is the world leader in biological solutions. Together with customers, partners, and the global community, we improve industrial performance while preserving the planet’s resources and helping build better lives. As the world’s largest provider of enzyme and microbial technologies, our bioinnovation enables higher agricultural yields, low-temperature washing, energy-efficient production, renewable fuel, and many other benefits that we rely on today and in the future.
For more Information: Sign-in Websites for Agrochemical & Pharmaceutical Databases:
Website: https://www.chemrobotics.com/ (Agrochemical Databases)
Website: https://chemroboticspharma.com/ (Pharmaceutical Databases)
